ALX Oncology Holdings Inc.

NasdaqGS:ALXO 주식 보고서

시가총액: US$76.4m

ALX Oncology Holdings 관리

관리 기준 확인 2/4

ALX Oncology Holdings CEO는 Jason Lettmann, Sep2023 에 임명되었습니다 의 임기는 1.17 년입니다. 총 연간 보상은 $ 5.32M, 4.1% 로 구성됩니다. 4.1% 급여 및 95.9% 보너스(회사 주식 및 옵션 포함). 는 $ 169.55K 가치에 해당하는 회사 주식의 0.22% 직접 소유합니다. 169.55K. 경영진과 이사회의 평균 재임 기간은 각각 2.5 년과 4.1 년입니다.

주요 정보

Jason Lettmann

최고 경영자

US$5.3m

총 보상

CEO 급여 비율4.1%
CEO 임기1.2yrs
CEO 소유권0.2%
경영진 평균 재임 기간2.5yrs
이사회 평균 재임 기간4.1yrs

최근 관리 업데이트

Recent updates

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

Sep 12

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Jun 27

ALX Oncology: Trying To Justify The Hype

Apr 18

Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?

Mar 12
Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?

ALX Oncology GAAP EPS of -$0.81 misses by $0.18

Aug 08

ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer

Aug 01

ALX Oncology stock rises 14% on evorpacept's FDA orphan drug status for blood cancer

Jun 29

ALX Oncology Is Turning Into An Also-Ran In Anti-CD47

Feb 15

ALX Oncology Stock: Attractive After Recent Data And Slump In Price

Nov 30

ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space

Sep 08

Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation

Jul 08
Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation

Dosing underway in ALX Oncology's ALX148 combo study in head and neck cancer

May 10

We're Not Very Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Rate

Mar 25
We're Not Very Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Rate

Here's What ALX Oncology Holdings Inc.'s (NASDAQ:ALXO) Shareholder Ownership Structure Looks Like

Feb 01
Here's What ALX Oncology Holdings Inc.'s (NASDAQ:ALXO) Shareholder Ownership Structure Looks Like

ALX Oncology: All Their Eggs In The Proverbial Basket

Jan 07

ALX Oncology (ALXO) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Dec 11

ALX Oncology prices upsized stock offering at $76

Dec 10

CEO 보상 분석

Jason Lettmann 의 보수는 ALX Oncology Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$171m

Mar 31 2024n/an/a

-US$166m

Dec 31 2023US$5mUS$217k

-US$161m

Sep 30 2023n/an/a

-US$146m

Jun 30 2023n/an/a

-US$130m

Mar 31 2023n/an/a

-US$129m

Dec 31 2022US$116kn/a

-US$123m

Sep 30 2022n/an/a

-US$121m

Jun 30 2022n/an/a

-US$110m

Mar 31 2022n/an/a

-US$94m

Dec 31 2021US$537kn/a

-US$83m

Sep 30 2021n/an/a

-US$74m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$58m

Dec 31 2020US$352kn/a

-US$51m

보상 대 시장: Jason 의 총 보상 ($USD 5.32M )은 US 시장( $USD 655.65K ).

보상과 수익: 회사가 수익성이 없는 동안 Jason 의 보상이 증가했습니다.

CEO

Jason Lettmann (47 yo)

1.2yrs

테뉴어

US$5,320,096

보상

Mr. Jason W. Lettmann had been an Independent Director of ALX Oncology Holdings Inc. since April 2020 until September 6, 2023 and previously served as a Director from March 2015 to May 2017 also serves as...

리더십 팀

이름위치테뉴어보상소유권
Jason Lettmann
CEO & Director1.2yrsUS$5.32m0.22%
$ 169.6k
Jaume Pons
Founder9.6yrsUS$2.75m0.88%
$ 669.2k
Peter Garcia
Chief Financial Officer4.8yrsUS$1.30m0.12%
$ 88.7k
Michael Chang
Vice President of Operationsno data데이터 없음데이터 없음
Shelly Pinto
Senior VP of Finance & Chief Accounting Officer3.5yrsUS$7.23m0.066%
$ 50.3k
Caitlyn Doherty
Manager of Investor Relations & Corporate Communicationsno data데이터 없음데이터 없음
Christopher Byrd
General Counsel2.5yrs데이터 없음데이터 없음
Athanasios Tsiatis
Senior Vice President of Clinical Development3yrs데이터 없음데이터 없음
Lin Yeong-Liang
Senior Vice President of Drug Safety & Pharmacovigilance2.4yrs데이터 없음데이터 없음
Lisa Sauer
Senior Vice President of Regulatory Affairs & Quality Assurance1.2yrs데이터 없음데이터 없음
Sue Naim
Senior Vice President of Clinical Operationsless than a year데이터 없음데이터 없음
Allison Dillon
Chief Business Officerless than a year데이터 없음데이터 없음

2.5yrs

평균 재임 기간

52.5yo

평균 연령

경험이 풍부한 관리: ALXO 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Jason Lettmann
CEO & Director4.6yrsUS$5.32m0.22%
$ 169.6k
Jaume Pons
Founder9.6yrsUS$2.75m0.88%
$ 669.2k
Corey Goodman
Chairman9.7yrsUS$206.61k0.32%
$ 242.7k
Alan Bart Sandler
Directorless than a year데이터 없음데이터 없음
Keith Flaherty
Chair of the Scientific Advisory Board4.1yrs데이터 없음데이터 없음
Scott Garland
Independent Director2yrsUS$105.66k0%
$ 0
Charles Baum
Member of the Scientific Advisory Board4.1yrs데이터 없음데이터 없음
Rekha Hemrajani
Independent Director4.6yrsUS$181.02k0.0057%
$ 4.4k
Kipp Weiskopf
Member of the Scientific Advisory Board4.1yrs데이터 없음데이터 없음

4.1yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 이사회: ALXO 의 이사회는 경험(평균 재직 기간 4.1 년)으로 간주됩니다.